The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center announced today that it has opened a new clinical trial that combines immunotherapy and surgery for the treatment of mesothelioma.
This is the first in-human study of neoadjuvant (before surgery) administration of a checkpoint inhibitor immunotherapy followed by surgical resection in patients with malignant pleural mesothelioma. The treatment focuses on the use of a preoperative boost to the immune system and cytoductive surgery with state-of-the art surgical techniques to combat the disease. The groundbreaking protocol will lay the foundation for multimodality therapy that includes using the patient’s own immune system in combination with surgical resection.
“We are very excited to be able to offer this trial to our patients. Much of our own data suggests that pleural mesothelioma may be a more immunogenic tumor than previously realized, and I predict that immunotherapy will rise to become a critical component of multimodality therapy for mesothelioma patients,” said Dr. Bryan Burt, assistant professor of surgery at Baylor College of Medicine and principal investigator of the trial. “This trial is one of the first of its kind in which immunotherapy is given before surgery, and from it, we expect to learn an enormous amount about this disease.”
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.